Table 1.
Features summary of the enrolled studies in the meta-analysis.
| Study(year) | Region | Gene | Number of patients | Sample type | Cut-off value | Detection method | Median follow-up monthes (minimum,maximum) | HR(95%CL) | Outcome | Quality | Hazard ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhou(2014)47 | China | MYC | 60 | FFPE | 50% | IHC | 24(4,62) | 11.862(1.462,96.218) | OS | 7 | R |
| Zijun(2015)48 | Western | BCL2 | 828 | FFPE | 70% | IHC | NR | 2.04(1.45,2.87) | OS | 7 | R |
| Lisa(2008)49 | America | MYC | 116 | FFPE | 50% | qNPA | NR | 1.64(1.16,2.31) | OS | 7 | R |
| America | BCL2 | 116 | FFPE | 50% | qNPA | NR | 1.11(0.77,1.60) | OS | 7 | R | |
| Iqbal(2011)50 | Mix | BCL2 | 221 | TISSUE | 50% | IHC | NR | 2.0(1.0,4.0) | OS | 7 | R |
| Johnson(2012)(T)18 | Mix | MYCBCL2 | 164 | FFPE | 40%50% | IHC | 42(6.24,135.6) | 4.27(2.18,8.37) | OS | 8 | SC |
| (V) | British | MYCBCL2 | 140 | FFPE | 40%50% | IHC | 56.4(12.0,96.0) | 1.47(0.75,2.87) | OS | 8 | SC |
| Ye(2015)51 | America | MYC | 825 | TISSUE | 70% | IHC | 58.9(1,187) | 1.89(1.26,3.94) | OS | 8 | R |
| America | BCL2 | 849 | TISSUE | 70% | IHC | 58.9(1,187) | 1.67(1.14,2.46) | OS | 8 | R | |
| America | MYCBCL2 | 831 | TISSUE | 70%70% | IHC | 58.9(1,187) | 2.54(1.65,3.94) | OS | 8 | R | |
| Scott(2015)52 | British | MYCBCL2 | 339 | FFPE | 40%50% | IHC | 78(9,158.4) | 1.9(1.4,3.1) | OS | 7 | R |
| Fan(2015)53 | China | MYC | 141 | FFPE | 40% | IHC | 30(3,112) | 3.127(1.649,5.929) | OS | 8 | R |
| China | BCL2 | 141 | FFPE | 50% | IHC | 30(3,112) | 0.934(0.465,1.875) | OS | 8 | R | |
| Perry(2013)(T)54 | America | MYC | 106 | FFPE | 50% | IHC | NR | 2.15(1.08,4.31) | OS | 7 | SC |
| America | BCL2 | 106 | FFPE | 30% | IHC | NR | 2.06(1.07,3.96) | OS | 7 | SC | |
| America | MYCBCL2 | 106 | FFPE | 50%30% | IHC | NR | 9.24(1.2,70.64) | OS | 7 | R | |
| (V) | British | MYCBCL2 | 205 | FFPE | 40%50% | IHC | NR | 2.79(0.37,21.38) | OS | 7 | R |
| Green(2012)(T)35 | Denmark | MYCBCL2 | 193 | FFPE | 40%70% | IHC | 56(1,99) | 4.48(2.69,7.44) | OS | 8 | R |
| (V) | Mix | MYCBCL2 | 116 | FFPE | 40%70% | IHC | 33(1,102) | 2.44(1.23,4.86) | OS | 8 | R |
| Hu(2013)17 | Mix | MYC | 466 | FFPE | 40% | IHC | 57 | 1.77(1.26,2.48) | OS | 8 | SC |
| Mix | BCL2 | 466 | FFPE | 70% | IHC | 57 | 2.00(1.45,2.74) | OS | 8 | SC | |
| Mix | MYCBCL2 | 411 | FFPE | 40%70% | IHC | 57 | 2.52(1.73,3.67) | OS | 8 | R | |
| Yan(2014)16 | China | MYC | 118 | FFPE | 40% | IHC | 37(1,145) | 4.12(1.86,9.10) | OS | 7 | R |
| China | BCL2 | 118 | FFPE | 70% | IHC | 37(1,145) | 1.48(0.71,3.07) | OS | 7 | R | |
| China | MYCBCL2 | 115 | FFPE | 40%70% | IHC | 37(1,145) | 2.67(1.60,4.48) | OS | 7 | R | |
| Xu(2017)55 | China | MYCBCL2 | 204 | FFPE | 40%70% | IHC | 40.5(0.6,154.2) | 2.384(1.222,4.652) | OS | 8 | R |
| Keisuke(2016)56 | Japan | MYC | 61 | FFPE | 30% | IHC | 40(2,127) | 1.361(0.556,3.334) | OS | 8 | R |
| Japan | BCL2 | 61 | FFPE | 1% | IHC | 40(2,127) | 3.481(1.158,10.46) | OS | 8 | R | |
| Kluk(2012)57 | America | MYC | 38 | FFPE | 50% | IHC | 31(2,69) | 5.22(0.35,77.47) | OS | 7 | SC |
| Horn(2013)15 | Germany | MYC | 135 | FFPE | 40% | IHC | NR | 2.3(1.2,4.7) | OS | 8 | R |
| Germany | BCL2 | 135 | FFPE | 1% | IHC | NR | 4.5(1.3,16.2) | OS | 8 | R | |
| Kendrick(2014)(I)58 | America | BCL2 | 44 | FFPE | 50% | IHC | NR | 0.983(0.285,3.395) | OS | 8 | R |
| (S) | America | BCL2 | 102 | FFPE | 50% | IHC | NR | 1.18(0.52,2.67) | OS | 8 | SC |
| Kelli(2015)59 | America | MYCBCL2 | 69 | FFPE | 40%50% | IHC | 4.25(0.14,12.85) | 2.63(1.07,6.44) | OS | 8 | R |
| Salles(2011)60 | Mix | BCL2 | 326 | FFPE | 75% | IHC | 4.4 | 1.4(0.9,2.2) | OS | 8 | R |
| Monette(2015)20 | Mix | MYC | 535 | TISSUE | 70% | IHC | 45(30,176.1) | 1.83(1.4,2.41) | OS | 8 | R |
IHC: Immunohistochemistry FFPE: formalin-fixed, paraffin-embedded tissue R: reported qNPA: quantitative nuclease protection assay SC: survival curve NR: not reported T: training set V: validation set I: initial cohort S: second cohort TMA: tissue microarrays.